Medtronic plc (NYSE:MDT) Given Average Recommendation of "Buy" by Analysts

Last updated on Sunday, February 28, 2021 | 2021 MarketBeat

Medtronic plc (NYSE:MDT) has received an average recommendation of "Buy" from the twenty-eight research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, nineteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $122.89.

MDT has been the topic of several recent analyst reports. Smith Barney Citigroup increased their price objective on Medtronic from $120.00 to $128.00 in a research report on Wednesday, November 25th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price objective on Medtronic from $120.00 to $128.00 in a research report on Wednesday, November 25th. UBS Group increased their price objective on Medtronic from $123.00 to $130.00 and gave the company a "buy" rating in a research report on Wednesday, November 25th. Truist increased their price objective on Medtronic to $128.00 and gave the company a "buy" rating in a research report on Wednesday, November 25th. Finally, Wells Fargo & Company raised their price target on Medtronic from $118.00 to $127.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 18th.

MDT traded down $0.91 during trading on Friday, reaching $116.97. 5,180,573 shares of the company were exchanged, compared to its average volume of 4,665,249. The company's 50-day moving average is $116.82 and its two-hundred day moving average is $110.55. The company has a market cap of $157.44 billion, a price-to-earnings ratio of 44.65, a P/E/G ratio of 3.65 and a beta of 0.70. The company has a quick ratio of 1.79, a current ratio of 2.16 and a debt-to-equity ratio of 0.52. Medtronic has a 12-month low of $72.13 and a 12-month high of $120.53.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 23rd. The medical technology company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.14. Medtronic had a return on equity of 9.71% and a net margin of 12.69%. The firm had revenue of $7.78 billion for the quarter, compared to analysts' expectations of $7.77 billion. During the same quarter last year, the firm posted $1.44 EPS. The company's revenue was up .8% compared to the same quarter last year. Equities analysts forecast that Medtronic will post 4.21 earnings per share for the current year.

In other news, EVP Robert John White sold 10,930 shares of the firm's stock in a transaction that occurred on Friday, December 18th. The stock was sold at an average price of $115.46, for a total value of $1,261,977.80. Following the completion of the transaction, the executive vice president now owns 55,852 shares in the company, valued at approximately $6,448,671.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Carol A. Surface sold 15,000 shares of Medtronic stock in a transaction on Monday, December 28th. The shares were sold at an average price of $114.90, for a total value of $1,723,500.00. The disclosure for this sale can be found here. Company insiders own 0.52% of the company's stock.

A number of large investors have recently made changes to their positions in MDT. Price T Rowe Associates Inc. MD increased its holdings in shares of Medtronic by 16.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,540,276 shares of the medical technology company's stock worth $2,406,046,000 after purchasing an additional 2,880,467 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Medtronic by 25.0% in the 4th quarter. Nuveen Asset Management LLC now owns 9,536,420 shares of the medical technology company's stock worth $1,117,096,000 after purchasing an additional 1,909,418 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Medtronic by 8.4% in the 4th quarter. Bank of New York Mellon Corp now owns 19,625,466 shares of the medical technology company's stock worth $2,298,927,000 after purchasing an additional 1,527,582 shares in the last quarter. Morgan Stanley increased its holdings in shares of Medtronic by 11.8% in the 4th quarter. Morgan Stanley now owns 11,560,485 shares of the medical technology company's stock worth $1,354,194,000 after purchasing an additional 1,221,333 shares in the last quarter. Finally, Coho Partners Ltd. bought a new stake in shares of Medtronic in the 3rd quarter worth $124,511,000. Institutional investors and hedge funds own 79.17% of the company's stock.

About Medtronic

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Featured Article: If I purchase shares through a brokerage account, am I the holder of record?

Analyst Recommendations for Medtronic (NYSE:MDT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Price Target



7 Outdoor Recreation Stocks For Growth And Dividends

If American’s liked outdoor activities before, they love them even more now. The COVID-19 pandemic has done many things, and one of them is reinvigorating American’s love of the outdoors. Data from across the industry shows a sustained uptick in revenue that has the entire complex moving higher.

The RV Industry Association, for example, reports shipments of RVs are up greater than 30% in 2020 and are expected to grow another 20% or more in 2021. If data from the two of the industry’s largest manufacturers are any indication, that forecast is very conservative.

And the gains aren’t limited to RVs. Everything that has anything to do with outdoor recreation is booming. Sales at Dicks Sporting Goods, an iconic brand for retail and the outdoors, has seen a sustained 20% increase in revenue since the 2nd quarter shutdowns. If anything, revenue in this sector is being held back by rapidly declining inventory and tight shipping conditions.

The stocks we are about to show all have something in common; the outdoors. Within the group, you will find everything from RVs to Radios and everything in between an outdoor enthusiast could need or want. Some pay dividends and some don’t, but all will deliver solid returns to investors in 2021.

View the "7 Outdoor Recreation Stocks For Growth And Dividends".


Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.